Su Yen Khong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Su Yen Khong has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Alan Lam
1 shared publication- Amphan Chalermchockcharoenkit
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Angela Aguilar
Department of Obstetrics and Gynecology, University of the Philippines College of Medicine, Philippine General Hospital, Manila (A.A.).
1 shared publication - Anthony Siow
ASC Clinic for Women Pte Ltd., Gleneagles Hospital, Singapore 258500, Singapore
1 shared publication - Areepan Sophonsritsuk
Reproductive Endocrinology and Infertility Unit, Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Bui Chi Thuong
University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam
1 shared publication
Latest Publications
- Open Access
- 12 December 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (12) , 2515
Clinical Diagnosis and Early Medical Management for Endometriosis: Consensus from Asian Expert Group
This work provides consensus guidance regarding clinical diagnosis and early medical management of endometriosis within Asia. Clinicians with expertise in endometriosis critically evaluated available evidence on clinical diagnosis and early medical management and their applicability to current clinical practices. Clinical diagnosis should focus on symptom recognition, which can be presumed to be endometriosis without laparoscopic confirmation. Transvaginal sonography can be appropriate for diagnosing pelvic endometriosis in select patients. For early empiric treatment, management of women with clinical presentation suggestive of endometriosis should be individualized and consider presentation and therapeutic need. Medical treatment is recommended to reduce endometriosis-associated pelvic pain for patients with no immediate pregnancy desires. Hormonal treatment can be considered for pelvic pain with a clinical endometriosis diagnosis; progestins are a first-line management option for early medical treatment, with oral progestin-based therapies generally a better option compared with combined oral contraceptives because of their safety profile. Dienogest can be used long-term if needed and a larger evidence base supports dienogest use compared with gonadotropin-releasing hormone agonists (GnRHa) as first-line medical therapy. GnRHa may be considered for first-line therapy in some specific situations or as short-term therapy before dienogest and non-steroidal anti-inflammatory drugs as add-on therapy for endometriosis-associated pelvic pain.
- 12 December 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (12) , 2515
Open AccessClinical Diagnosis and Early Medical Management for Endometriosis: Consensus from Asian Expert Group
This work provides consensus guidance regarding clinical diagnosis and early medical management of endometriosis within Asia. Clinicians with expertise in endometriosis critically evaluated available evidence on clinical diagnosis and early medical management and their applicability to current clinical practices. Clinical diagnosis should focus on symptom recognition, which can be presumed to be endometriosis without laparoscopic confirmation. Transvaginal sonography can be appropriate for diagnosing pelvic endometriosis in select patients. For early empiric treatment, management of women with clinical presentation suggestive of endometriosis should be individualized and consider presentation and therapeutic need. Medical treatment is recommended to reduce endometriosis-associated pelvic pain for patients with no immediate pregnancy desires. Hormonal treatment can be considered for pelvic pain with a clinical endometriosis diagnosis; progestins are a first-line management option for early medical treatment, with oral progestin-based therapies generally a better option compared with combined oral contraceptives because of their safety profile. Dienogest can be used long-term if needed and a larger evidence base supports dienogest use compared with gonadotropin-releasing hormone agonists (GnRHa) as first-line medical therapy. GnRHa may be considered for first-line therapy in some specific situations or as short-term therapy before dienogest and non-steroidal anti-inflammatory drugs as add-on therapy for endometriosis-associated pelvic pain.
- 1 May 2011
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 18 (3) , 333-337
Is Pouch of Douglas Obliteration a Marker of Bowel Endometriosis?
- 1 May 2011
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 18 (3) , 333-337
Is Pouch of Douglas Obliteration a Marker of Bowel Endometriosis?